Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx věcí,
xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. a x. 46/2008 Sb. x. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 97/2012 Sb. x. x. x Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 12. listopadu 2012 xxxx generální ředitelkou XXXXXX oznámeno schválení xxxxxx znění Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu ve xxxxxx1).
S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Nové xxxxx Přílohy X xxxxxxxxx x platnost x xxxxxxx s xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2013 x xxxxx dnem xxxxxxxxx x xxxxxxxx x xxx Českou xxxxxxxxx. Dnem xxxxxx xxxxxx znění Přílohy X x xxxxxxxx xxxxxxxx platit znění Xxxxxxx X Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx xxxxxx xx 1. xxxxx 2012 a vyhlášené xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x její xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx xxxxx dopingu xx sportu xxxxxxx xxx 19. října 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
XXXXXXX I
XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX XXX 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx M1, X2 x M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(XXX XXXXXXX X XXXX XXXXXX)
|
XXXXXXXX XXXXX
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým regulačním xxxxxx (např. léčiva x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx výzkumu xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx stále.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (XXX):
(x) Xxxxxxxx* AAS, zahrnující:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; mesterolon; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-dion); xxxxxxxxxx; norethandrolon; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx a xxxxxx xxxxxxxxxx a xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Ostatní anabolické xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx na xx.
| &xxxx;
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx normálně schopno xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k látce, xxxxxx může tělo xxxxxxxxxx xxxxxxxxx.
|
X2. PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), darbepoetin (xXXX), stabilizátory xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) a Xxxxxxxxxxxx xxxxxx (XX) x mužů;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), fibroblastové xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx faktor-1 (XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx degradaci bílkovin xxxxx, xxxxx a xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 agonisté xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x l-), xxxx xxxxxxxx xxxxx salbutamolu (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx za 24 xxxxx) x xxxxxxxxxxx xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x doporučeným xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx salbutamolu x xxxx v koncentraci xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx terapeutické xxxxxxx, xxx bude považována xx xxxxxxxxx laboratorní xxxxx, pokud xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx byl způsoben xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx než xxxx uvedené xxxxxxx.
X4. HORMONOVÉ A XXXXXXXXXXX XXXXXXXXXX
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, toremifen, xxx xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx antiestrogenní xxxxx zahrnující:
Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx xx s omezením xxxxx xx xx.
4. Xxxxx modifikující xxxxxx myostatinu včetně xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx:
x) Insuliny;
x) Xxxxxxxx delta xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x součinnosti s XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. DIURETIKA X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx a mannitolu), xxxxxxxxxx a xxxxx xxxxx x podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx felypressinu xxx xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, bumetanid, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx nejsou xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx prahovým limitem (xx. formoterol, salbutamol, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx látku navíc x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx maskovací látku.
ZAKÁZANÉ XXXXXX
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.
2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x xxxxxxxx xxxxx xx ně. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.
3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.
X2. XXXXXXXX X XXXXXXXXX MANIPULACE
Zakázané xx následující:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x platnost Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx úpravu (xxxx. xxxxxxxxxx) xxxx, ale xx s omezením xxxxx xx ně.
2. Xxxxxxxxxx xxxxxx x/xxxx injekce xxxx xxx 50 xx xx 6 hodin xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx přijatých x průběhu nemocničních xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxx metod.
M3. XXXXXX XXXXXX
X xxxxxx potenciálu xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Transfer nukleových xxxxxxx nebo xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X XXXXXX XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx xxxx jsou Xxx Xxxxxxx zakázané x xxxxxxxxxxx xxxxxxx:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- x x-) xxxx zakázaná, x xxxxxxxx derivátů xxxxxxxxx x případě xxxxxx místního použití x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(a) Xxxxxxxxxxxx stimulancia:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (karfedon), furfenorex, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Specifickou xxxxxx.
(x) Specifická stimulancia (xxxxxxxx):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, isomethepten, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, pemolin, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****selegilin, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan a xxxxx látky x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx biologickými xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (např. xxxxx, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx zakázáno.
*** Xxxxx je xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx než 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx a methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x moči xx vyšší xxx 150 mikrogramů xx xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx xx následujíci:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, konopí x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ a XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, nitrožilní nebo xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
| &xxxx;
LÁTKY ZAKÁZANÉ X URČITÝCH XXXXXXXX
|
P1. XXXXXXX
Xxxxxxx (xxxxxx) je xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx porušeni dopingového xxxxxxxx (hematologická xxxxxxx) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Karate (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Xxxxxxxxxxx sport (XXX)
∙ Vodní xxxxxxxxxx (UIM)
P2. XXXX-XXXXXXXXX
Xxxxx není xxxxx určeno, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx sport (XXX)
∙ Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)
∙ Xxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x snowboard U-rampa x "xxx air"
∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxx (XXX)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, bunolol, xxxxxxxxxx, esmolol, karteolol, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis x. 98/2013 Xx. m. x. nabyl účinnosti xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného právního xxxxxxxx.